Design and development of novel therapeutics for coronary heart disease treatment based on cholesteryl ester transfer protein inhibition - in silico approach

被引:4
|
作者
Kostic, Tomislav [1 ]
Ilic, Marina Deljanin [2 ]
Perisic, Zoran [1 ]
Milic, Dragan [3 ]
Dordevic, Miodrag [4 ]
Golubovic, Mladjan [5 ]
Koracevic, Goran [1 ]
Martinovic, Sonja Salinger [1 ]
Zdravkovic, Snezana Ciric [1 ]
Zivic, Sasa [3 ]
Lazarevic, Milan [3 ]
Stanojevic, Dragana [1 ]
Dakic, Sonja [1 ]
Lilic, Jelena [5 ]
Veselinovic, Aleksandar [6 ]
机构
[1] Clin Ctr Nis, Clin Cardiovasc Dis, Nish, Serbia
[2] Inst Cardiovasc Prevent & Rehabil Niska Banja, Nish, Serbia
[3] Clin Ctr Nis, Clin Cardiovasc Surg, Nish, Serbia
[4] Clin Ctr Nis, Clin Endocrine Surg & Breast Surg, Nish, Serbia
[5] Clin Ctr Nis, Clin Anesthesiol & Intens Care, Nish, Serbia
[6] Univ Nis, Fac Med, Dept Chem, Bulevar Dr Zorana Dindica 81, Nish 18000, Serbia
来源
关键词
Cholesteryl ester transfer protein inhibitors; coronary heart disease therapy; QSAR; molecular modeling; drug design; MONTE-CARLO METHOD; DRUG DISCOVERY; VARIABLE SELECTION; QSAR; HDL; VALIDATION; PRINCIPLES; DOCKING; 3D-QSAR; TARGET;
D O I
10.1080/07391102.2019.1630319
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesteryl ester transfer protein (CETP) belongs to the group of enzymes which inhibition have the application in the treatment of cardiovascular diseases. This study presents QSAR modeling for a set of compounds acting as CETP inhibitors based on the Monte Carlo optimization with SMILES notation and molecular graph-based descriptors, and field-based 3D modeling. A 3D QSAR model was developed for one random split into the training and test sets, whereas conformation independent QSAR models were developed for three random splits, with the results suggesting there is an excellent correlation between them. Various statistical approaches were used to assess the statistical quality of the developed models, including robustness and predictability, and the obtained results were very good. This study used a novel statistical metric known as the index of ideality of correlation for the final assessment of the model, and the results that were obtained suggested that the model was good. Also, molecular fragments which account for the increases and/or decreases of a studied activity were defined and then used for the computer-aided design of new compounds as potential CETP inhibitors. The final assessment of the developed QSAR model and designed inhibitors was done using molecular docking, which revealed an excellent correlation with the results from QSAR modeling. Communicated by Ramaswamy H. Sarma
引用
收藏
页码:2304 / 2313
页数:10
相关论文
共 50 条
  • [1] Cholesteryl ester transfer protein in patients with coronary heart disease
    Duwensee, Kristina
    Breitling, Lutz Philipp
    Tancevski, Ivan
    Rothenbacher, Dietrich
    Demetz, Egon
    Patsch, Josef R.
    Ritsch, Andreas
    Eller, Philipp
    Brenner, Hermann
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2010, 40 (07) : 616 - 622
  • [2] Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: Real hope or despair?
    Frishman, William H.
    Barkowski, Rakhi Shah
    AMERICAN JOURNAL OF MEDICINE, 2008, 121 (08): : 644 - 646
  • [3] Inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease
    Doggrell, SA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (02) : 99 - 106
  • [4] The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease
    Bochem, A. E.
    Kuivenhoven, A.
    Stroes, E. S. G.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (17) : 3143 - 3149
  • [5] Cholesteryl ester transfer protein inhibition - The next frontier in combating coronary artery disease?
    Milani, Richard V.
    Lavie, Carl J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (09) : 1791 - 1792
  • [6] Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk
    Barter, Philip J.
    Rye, Kerry-Anne
    CARDIOLOGY CLINICS, 2018, 36 (02) : 299 - +
  • [7] Cholesteryl ester transfer protein gene and coronary heart disease mortality: The rotterdam study
    Silva, M. Carolina Pardo
    Janssens, A. Cecile J. W.
    Hofman, Albert
    Witteman, Jacqueline C. M.
    van Duijn, Cornelia M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (09) : 1483 - 1484
  • [8] Development and design of novel cardiovascular therapeutics based on Rho kinase inhibition In-silico approach
    Zdravkovic, Snezana Ciric
    Pavlovic, Milan
    Apostlovic, Svetlana
    Koracevic, Goran
    Martinovic, Sonja Salinger
    Stanojevic, Dragana
    Sokolovic, Dugan
    Veselinovic, Aleksandar M.
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2019, 79 : 55 - 62
  • [9] Inhibitors of cholesteryl ester transfer protein - a step forward in the treatment of coronary artery disease?
    Doggrell, SA
    DRUGS OF THE FUTURE, 2005, 30 (01) : 45 - 50
  • [10] Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease
    Nomura, Akihiro
    Won, Hong-Hee
    Khera, Amit V.
    Takeuchi, Fumihiko
    Ito, Kaoru
    McCarthy, Shane
    Emdin, Connor A.
    Klarin, Derek
    Natarajan, Pradeep
    Zekavat, Seyedeh M.
    Gupta, Namrata
    Peloso, Gina M.
    Borecki, Ingrid B.
    Teslovich, Tanya M.
    Asselta, Rosanna
    Duga, Stefano
    Merlini, Piera A.
    Correa, Adolfo
    Kessler, Thorsten
    Wilson, James G.
    Bown, Matthew J.
    Hall, Alistair S.
    Braund, Peter S.
    Carey, David J.
    Murray, Michael F.
    Kirchner, H. Lester
    Leader, Joseph B.
    Lavage, Daniel R.
    Manus, J. Neil
    Hartze, Dustin N.
    Samani, Nilesh J.
    Schunkert, Heribert
    Marrugat, Jaume
    Elosua, Roberto
    McPherson, Ruth
    Farrall, Martin
    Watkins, Hugh
    Juang, Jyh-Ming J.
    Hsiung, Chao A.
    Lin, Shih-Yi
    Wang, Jun-Sing
    Tada, Hayato
    Kawashiri, Masa-aki
    Inazu, Akihiro
    Yamagishi, Masakazu
    Katsuya, Tomohiro
    Nakashima, Eitaro
    Nakatochi, Masahiro
    Yamamoto, Ken
    Yokota, Mitsuhiro
    CIRCULATION RESEARCH, 2017, 121 (01) : 81 - +